Back to Ovarian Cancer
This trial is complete. It is no longer accepting participants. Results may be available on ClinicalTrials.gov.

NCT00189566

NCT00189566
Completed Phase 2

Who may be able to join

Who might be able to join this trial:

  • You are over 18 years old
  • You have been diagnosed with cancer of the ovary, fallopian tube, or peritoneum, confirmed by a laboratory test on tissue
  • Your cancer has spread to the lining of the abdomen, lymph nodes, or other organs
  • Your cancer has gotten worse during treatment, or came back within 6 months after your first or second chemotherapy treatment containing platinum
  • It has been at least 3 weeks since your last chemotherapy session
  • Your cancer can be measured on a scan or tracked using a blood marker called CA-125
  • You are reasonably active and able to carry out daily activities (confirm with trial site)
  • Doctors expect you to live for at least 12 weeks

Who may not be able to join:

  • You have previously received a specific form of paclitaxel chemotherapy given on a weekly schedule
  • You are currently taking part in another clinical trial, or have done so in the last 30 days
  • You have had a bone marrow transplant using your own cells, or radiation to your abdomen, within the last 5 years
  • You have previously had another type of cancer
  • You have a history of heart problems, such as heart disease, heart failure, irregular heartbeat, high blood pressure, or significant heart valve problems
  • You have existing nerve problems affecting movement or sensation that are more than mild in severity
  • You have significant problems with your bone marrow, kidneys, or liver function
  • You have a serious active infection, or a blockage in your bowel (full or partial)
  • You have had brain tumours that caused symptoms
  • You are a woman who could become pregnant and are not using a reliable method of contraception
  • You are pregnant or currently breastfeeding
  • You have had a serious allergic reaction to paclitaxel, topotecan, carboplatin, or any closely related medicines

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Trial details

Status
Completed
Phase
Phase 2
Sponsor
ARCAGY/ GINECO GROUP
Registry
clinicaltrials_gov
Start date
1 April 2004

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Progression-free survival of patients in the three groups

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov